Vivos Therapeutics, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Bradford Amman resigned as CFO effective July 31, 2026, receiving $80K in transition pay (90 days at $320K base), 250,000 vested shares, 150,000 options vesting monthly, and 6 months of advisory services at $13,333/month. Simultaneously, Vivos engaged The CFO Portal, LLC to provide managed CFO services via Roman Franklin (Engagement Lead) at $27,000/month retainer, plus 552,000 stock options vesting over 12 months at market price. Franklin is appointed CFO/PFO; Amman transitions to Principal Accounting Officer. Both agreements dated July 31, 2026.
Why this rating
For a $22.9M market-cap company, a $27K/month CFO outsourcing contract (~$324K/year) plus 552K options and Amman's severance ($80K + equity) represent ~1.4-2% of market cap in annual cash outflow, material for continuity. Leadership transition is significant but orderly transition structure mitigates risk. Options dilution (702K shares combined) is notable but not disclosed % of total shares outstanding.
Extracted items
- 5.02 exec change
- 1.05
- 2.02 results / earnings
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.